Bodovitz Steven, Joos Thomas, Bachmann Jutta
BioPerspectives, 2040 Hyde Street, San Francisco, CA 94109, USA.
Drug Discov Today. 2005 Feb 15;10(4):283-7. doi: 10.1016/S1359-6446(05)03373-8.
The growth of protein biochip technology is on a different trajectory than other drug discovery and development technologies, such as DNA sequencing and high-throughput screening, where output per experiment has grown exponentially. By contrast, experimentation with protein biochips immediately hit barriers in output because of the limited availability of content and the challenges of running biochemical experiments on the surface of a biochip. Nevertheless, the industry has been making significant progress recently by launching new platforms with focused content and new multiplexed biochemical assays. However, this success might only represent the calm before the storm. Over the long-term, protein biochips have the potential to change the drug discovery and development process at the molecular level. The output and throughput of protein biochips could enable researchers to change from the traditional model of one target-one drug to a new model of evaluating one or more potential drugs against a panel of relevant molecular targets from a complex disease state.
蛋白质生物芯片技术的发展轨迹与其他药物发现和开发技术不同,例如DNA测序和高通量筛选,后者每次实验的产出呈指数级增长。相比之下,由于可用内容有限以及在生物芯片表面进行生化实验面临挑战,蛋白质生物芯片的实验产出立即遇到了障碍。尽管如此,该行业最近通过推出具有针对性内容的新平台和新的多重生化分析方法取得了重大进展。然而,这种成功可能只是暴风雨前的平静。从长远来看,蛋白质生物芯片有潜力在分子水平上改变药物发现和开发过程。蛋白质生物芯片的产出和通量可以使研究人员从传统的一个靶点一种药物模式转变为针对复杂疾病状态下一组相关分子靶点评估一种或多种潜在药物的新模式。